2024-06-18T13:42:17-05:00 2023-12-31 BDO USA 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2023-01-01 526063009 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA FDN INC % TRACEY MERCHANT PHAR 2025727755 670 MAINE AVENUE SW Suite 1000 WASHINGTON DC 20024 AMY MILLER PRESIDENT 2025727755 2024-06-18 true AMY MILLER XXX-XX-XXXX true Marc Berger P01871563 7038930600 2024-04-30 2 2023 2023-04-26 12:10:37Z X AMY MILLER 670 MAINE AVENUE SW1000 WASHINGTON DC 20024 9644463 false X WWW.PHRMAFOUNDATION.ORG X 1965 DC SEE SCHEDULE O 9 9 4 99 0 0 3535607 3576216 0 0 367035 668514 0 0 3902642 4244730 2649027 2952608 0 0 910758 1052004 0 0 3313 518206 361391 4077991 4366003 -175349 -121273 22787225 24481309 1467134 404521 21320091 24076788 X THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE. true true 1007676 799168 0 DRUG DISCOVERY - SUPPORTS EARLY CAREER RESEARCHERS WHOSE RESEARCH CAN HELP ACCELERATE BIOLOGICAL VALIDATION OF POTENTIAL DRUG TARGETS, SIGNALING PATHWAYS, OR MECHANISMS OF DISEASE. 1035926 797500 0 VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH - SUPPORTS RESEARCHERS INVESTIGATING CHALLENGES IN EVALUATING THE DELIVERY, SAFETY, EFFECTIVENESS, AND VALUE OF HEALTH CARE INTERVENTIONS. 847377 677500 0 DRUG DELIVERY - SUPPORTS EARLY CAREER RESEARCHERS STUDYING WAYS TO OPTIMIZE DRUG COMPOSITION, DOSAGE, AND DELIVERY TO MAKE TREATMENTS SAFER, MORE EFFECTIVE, AND EASIER TO MANAGE FOR PATIENTS. 621230 492440 0 TRANSLATIONAL MEDICINE 218716 175000 0 DIGITAL HEALTH TECHNOLOGIES 89289 11000 0 Other Programs 929235 678440 0 3820214 true true false false false false false false false false true false false false true true true false false false false false false false false false false true true true false false false false false false false false false false false false false false false false false true 42 0 true 4 true false false false false false false false false false false false false X 9 9 false false false false false true false true true false false true true true true true true true true false CA CT IL MD MA NJ NY NC PA X TRACEY MERCHANT 2028353400 670 MAINE AVE SW SUITE 1000 WASHINGTON DC 20024 X AMY MILLER PRESIDENT 37.5 0.0 X 473105 0 71183 Emily Ortman Senior Director 37.5 0.0 X 181481 0 56873 Joanne Westphal Director 37.5 0.0 X 171183 0 34576 Andrew Plump MD PhD Chairman 1.0 0.0 X X 0 0 0 Iris Loew-Friedrich MD Treasurer 1.0 0.0 X X 0 0 0 George Addona PhD Director 1.0 0.0 X 0 0 0 Aida Habtezion MD MSc FRCP Director 1.0 0.0 X 0 0 0 Aran Maree MB BCH MRCIP Director 1.0 0.0 X 0 0 0 Robert Plenge MD PhD Director 1.0 0.0 X 0 0 0 Maha Radhakrishnan MD Director 1.0 0.0 X 0 0 0 Daniel Skovronsky MD PhD Director 1.0 0.0 X 0 0 0 John Creed MD PHD Director (thru 2/28/2023) 1.0 0.0 X 0 0 0 Rupert Vessey MA BM BCh Director (thru 6/4/2023) 1.0 0.0 X 0 0 0 Lori Reilly Esq Ex Officio member 1.0 0.0 X 0 0 0 825769 0 162632 3 false true false O'Connor Consulting Services LLC 6507 Marjory Lane BETHESDA MD 20817 ACCOUNTING SERVICES 108285 1 3576216 3576216 0 496762 0 496762 0 0 0 0 0 5571485 5399733 171752 171752 171752 0 0 0 0 0 0 0 0 0 0 4244730 0 668514 206000 206000 2746608 2746608 0 0 544288 377264 167024 0 334773 232043 102730 68411 47418 20993 58851 40792 18059 45681 31663 14018 0 0 32011 32011 0 0 22013 22013 163297 28650 134647 18633 18633 1699 1527 172 32243 26206 6037 0 0 29969 19987 9982 0 23590 22838 752 0 0 5454 3780 1674 8735 6055 2680 DUES/PUBLICATIONS/PROJECTS 15591 10750 1528 3313 BANK/PAYROLL CHARGES 8156 8156 4366003 3820214 542476 3313 2182721 1396883 0 0 0 0 0 0 0 0 0 0 0 0 0 0 31531 20886 98178 5454 92724 20572973 22970816 0 0 0 0 0 0 0 0 22787225 24481309 1421900 374751 0 0 0 0 0 0 0 0 0 0 0 0 0 0 45234 29770 1467134 404521 X 21320091 24076788 0 0 21320091 24076788 22787225 24481309 X -121273 2840236 37734 X X false true X true false X 2940620 3937859 2764822 3535607 3576216 16755124 0 0 2940620 3937859 2764822 3535607 3576216 16755124 10827812 5927312 578459 477282 407496 460897 496762 2420896 0 144775 0 0 0 0 144775 19320795 0.30678 0.32177 X SCHEDULE A, PART II, FACTS AND CIRCUMSTANCES TEST PART II, SECTION C, LINE 17A, FACTS AND CIRCUMSTANCES TEST: THE FOUNDATION CONTINUES TO SOLICIT FUNDS FROM NEW SUPPORTERS IN THE PHARMACEUTICAL AND RELATED RESEARCH FIELDS USING A VARIETY OF OUTREACH METHODS. THE FOUNDATION ROUTINELY ATTENDS AND SPONSORS INDUSTRY CONFERENCES TO PROMOTE ITS GRANTS AND AWARDS PROGRAM AND NETWORK WITH INDUSTRY PEERS AND DONORS. EXPANSION OF FOUNDATION STAFF INCLUDES A SENIOR DIRECTOR WHO CREATES FUNDRAISING RELATED MATERIALS. THE FOUNDATION'S BOARD MEMBERS REGULARLY IDENTIFY FUNDRAISING OUTREACH STRATEGIES. THE FOUNDATION DISTRIBUTES A REGULAR NEWSLETTER TO PROMOTE THE FOUNDATION AND ENGAGE WITH POTENTIAL NEW DONORS. THE FOUNDATION OPERATES IN THE PUBLIC'S INTEREST BY ADMINISTERING A GRANT AND AWARD PROGRAM AVAILABLE TO ELIGIBLE CANDIDATES ACROSS THE UNITED STATES. THE FOUNDATION ACTIVELY SEEKS WAYS TO EXPAND OUTREACH AND INCREASE APPLICATION RATES AMONG HISTORICALLY UNDERREPRESENTED GROUPS AND SUPPORTS THE PUBLICATION OF AWARDEE RESEARCH FINDINGS. THE FOUNDATION WORKS WITH GOVERNMENTAL AGENCIES ON RESEARCH REQUESTS TO HELP INFORM REGULATORY DECISIONS. THE FOUNDATION ALSO PROVIDES FREE EDUCATIONAL RESOURCES TO THE GENERAL PUBLIC THROUGH ITS WEBSITE AND WEBINARS. THE FOUNDATION'S BOARD OF DIRECTORS CONSISTS OF RESEARCH AND DEVELOPMENT EXECUTIVES AND CHIEF MEDICAL OFFICERS OF BIOPHARMACEUTICAL COMPANIES, ALL OF WHOM HAVE SPECIALIZED KNOWLEDGE AND EXPERTISE IN THE FIELD OF PHARMACEUTICAL RESEARCH. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 98178 5454 92724 92724 0 INTERCOMPANY SETTLEMENT 29770 29770 X 7127340 2840236 64387 2904623 4222717 22013 22013 4244730 4370643 64387 -37734 26653 4343990 22013 22013 4366003 SCHEDULE D, PART X, LINE 2: MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND CONCLUDED THAT THE FOUNDATION HAS NOT TAKEN ANY UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE FINANCIAL STATEMENTS. AT A MINIMUM, THE TAX PERIODS ENDED DECEMBER 31, 2020 AND LATER ARE OPEN FOR EXAMINATION BY TAXING AUTHORITIES. SCHEDULE D, PART XII, LINE 2D: Refunded Grants of $37,734 true University of Southern California Keck School of Univ GRDNS Ste 205 Los Angeles CA 90089 951642394 501(c)(3) 25000 Digital Health Technology Planning grant Northwestern Memorial Foundation 541 N Fairbanks Court Chicago IL 60611 363155315 501(c)(3) 25000 Digital Health Technology Planning grant Johns Hopkins University 3910 Keswick Road Baltimore MD 21211 520595110 501(c)(3) 25000 Digital Health Technology Planning grant The University of Texas at Austin 110 Inner Campus Dr Austin TX 78712 746000203 State Agency 25000 Digital Health Technology Planning grant Honor Health Research Institute 10510 N 92nd St Scottsdale AZ 85258 860181654 501(c)(3) 25000 Digital Health Technology Planning grant State University of Iowa 105 Jessup Hall Ioway City IA 52242 426004813 State Agency 25000 Digital Health Technology Planning grant The Ohio State University 901 Woody Hays Dr Columbus OH 43210 316025986 State Agency 25000 Digital Health Technology Planning grant The Brigham and Women's Hospital Inc 75 Francis Street Boston MA 02115 042312909 501(c)(3) 15000 Challenge award AFPE(American Foundation for Pharmaceutical Educ) 11325 Random Hills Road Fairfax VA 22030 530214882 501(c)(3) 11000 Pre-doctoral fellowship program 9 Value Assessment-Health Outcomes Research 32 779940 TRANSLATIONAL MEDICINE 12 490000 Drug Delivery 16 677500 Drug Discovery 26 799168 SCHEDULE I, PART I, LINE 2: THE GRANTS AND FELLOWSHIPS ARE AWARDED WITH INFORMATION ON HOW THE FUNDS MAY BE SPENT AND ADMINISTERED. THE SECOND YEAR OF FUNDING, IF APPLICABLE, IS CONTINGENT UPON A SATISFACTORY REVIEW OF THE AWARD RECIPIENT'S PROGRESS DURING THE FIRST TEN MONTHS OF FUNDING. A PROGRESS REPORT IS DUE TO THE FOUNDATION PRIOR TO THE BEGINNING OF THE SECOND YEAR OF FUNDING. THE PROGRESS IS ASSESSED BY THE ADVISORY COMMITTEE. THE DECISION TO CONTINUE THE FUNDING IS BASED ON ADHERENCE TO THE GOALS OF THE ANNOUNCEMENT OF THE OVERALL PROGRAM, AND ALSO IN KEEPING WITH THE ORIGINALLY PROPOSED RESEARCH ON WHICH THE AWARD WAS BASED. IN ADDITION TO THE PROGRESS REPORT, THE FOUNDATION MUST RECEIVE CERTIFICATION FROM THE THESIS ADVISOR THAT SATISFACTORY PROGRESS IS BEING ACHIEVED IF IT IS THE PRE DOCTORAL FELLOWSHIP. A FINANCIAL REPORT IS ALSO DUE TO THE FOUNDATION AFTER THE FIRST YEAR OF FUNDING AND FOLLOWING THE END OF THE FUNDING PERIOD FOR ALL AWARDS. THE INSTITUTION MUST STIPULATE THE AMOUNT OF FUNDS RECEIVED BY THE UNIVERSITY, HOW THE FUNDS HAVE BEEN USED/SPENT AND IF THERE IS A REMAINING BALANCE ON THE ACCOUNT. SCHEDULE I, PART III: TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. DRUG DELIVERY - SUPPORTS EARLY CAREER RESEARCHERS STUDYING WAYS TO OPTIMIZE DRUG COMPOSITION, DOSAGE, AND DELIVERY TO MAKE TREATMENTS SAFER, MORE EFFECTIVE, AND EASIER TO MANAGE FOR PATIENTS. DRUG DISCOVERY - SUPPORTS EARLY CAREER RESEARCHERS WHOSE RESEARCH CAN HELP ACCELERATE BIOLOGICAL VALIDATION OF POTENTIAL DRUG TARGETS, SIGNALING PATHWAYS, OR MECHANISMS OF DISEASE. VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH - SUPPORTS RESEARCHERS INVESTIGATING CHALLENGES IN EVALUATING THE DELIVERY, SAFETY, EFFECTIVENESS, AND VALUE OF HEALTH CARE INTERVENTIONS. X true true X X false false false false false false false false false AMY MILLER PRESIDENT 341978 0 128989 0 2138 0 33000 0 38183 0 544288 0 0 0 Emily Ortman Senior Director 155971 0 22881 0 2629 0 17372 0 39501 0 238354 0 0 0 Joanne Westphal Director 148596 0 19115 0 3472 0 17541 0 17035 0 205759 0 0 0 SCHEDULE J, PART I, LINE 1: One first class airline ticket was purchased for the President in 2023. This was a last minute ticket, cheaper than coach seats on sale at that late date. This amount was not included in taxable compensation. FORM 990, PART I, LINE 1: DESCRIPTION OF ORGANIZATION MISSION THE PHRMA FOUNDATION WORKS TO IMPROVE PUBLIC HEALTH BY PROACTIVELY INVESTING IN INNOVATIVE RESEARCH, EDUCATION AND VALUE-DRIVEN HEALTH CARE. FORM 990, PART III, LINE 2: DIGITAL HEALTH TECHNOLOGIES: SUPPORTS RESEARCH ON THE USE OF DHTS IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. FORM 990, PART III, LINE 3: THE TWO SEPARATE VALUE ASSESSMENT AND HEALTH OUTCOMES RESEARCH PROGRAMS WERE COMBINED TO CREATE ONE PROGRAM NAMED VALUE ASSESSMENT-HEALTH OUTCOMES RESEARCH. MINOR GRANTS WILL BE PAID OUT THROUGH 2024, BUT ALL EXPENSES WILL BE REPORTED UNDER NEW PROGRAM. PHARMACEUTICS, INFORMATICS, AND PHARMACOLOGY/TOXICOLOGY PROGRAMS ALSO ENDED. FORM 990, PART III, LINE 4D: TRANSLATIONAL MEDICINE - SUPPORTS EARLY CAREER INVESTIGATORS CONDUCTING NOVEL RESEARCH THAT USES THE "BEDSIDE TO BENCH" APPROACH TO ADDRESS UNMET NEEDS IN THE DIAGNOSIS, TREATEMENT, AND PREVENTION OF DISEASE. EXPENSES $ 621,230. GRANTS $ 492,440. REVENUE $ 0. DIGITAL HEALTH TECHNOLOGIES: SUPPORTS RESEARCH ON THE USE OF DHTs IN UNDERREPRESENTED POPULATIONS IN CLINICAL TRIALS TO ADVANCE FDA REGULATORY DECISION MAKING. EXPENSES $ 218,716. GRANTS $ 175,000. REVENUE $ 0. OTHER PROGRAMS EXPENSES $ 89,289. GRANTS $ 11,000. REVENUE $ 0. FORM 990, PART VI, SECTION A, LINE 7A: THE CHIEF OPERATING OFFICER OF THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), A SECTION 501(C)(6) TRADE ASSOCIATION THAT HAS A HISTORIC AND CONTINUING RELATIONSHIP WITH THE FOUNDATION, IS AN EX-OFFICIO MEMBER OF THE FOUNDATION'S BOARD OF DIRECTORS. FOUNDATION DIRECTORS MUST BE RESEARCH AND DEVELOPMENT EXECUTIVES OR CHIEF MEDICAL OFFICERS OF COMPANIES THAT ARE MEMBERS OF PHRMA, BUT ARE ELECTED BY THE FOUNDATION BOARD ITSELF. FORM 990, PART VI, SECTION B, LINE 11B: THE FOUNDATION FORM 990 IS PREPARED BY BDO USA, CPAS, AND REVIEWED INTERNALLY BY KEY FINANCIAL MANAGEMENT AND THE FOUNDATION'S PRESIDENT. A COPY OF THE 990 IS PROVIDED TO THE BOARD OF DIRECTORS TO REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C: ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES OF THE FOUNDATION MUST REPORT POTENTIAL AND ACTUAL CONFLICTS AS THEY ARISE. IN ADDITION, THEY ARE REQUIRED TO SIGN AN ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT. WHEN A POTENTIAL CONFLICT OF INTEREST IS DISCLOSED TO, OR OTHERWISE COMES TO THE ATTENTION OF, THE PRESIDENT, THE CHAIR OF THE BOARD OR AN ON-AFFECTED DIRECTOR, HE OR SHE SHALL CONSIDER ALL THE RELEVANT CIRCUMSTANCES AND SHALL DETERMINE WHETHER THE ARRANGEMENT IS POTENTIALLY HARMFUL TO THE BEST INTERESTS OF THE FOUNDATION. IF THE ARRANGEMENT IS FOUND NOT TO BE HARMFUL, THEN THE ARRANGEMENT MAY BE AUTHORIZED OR APPROVED; OTHERWISE, THE DIRECTOR, OFFICER OR KEY EMPLOYEE WHO IS INVOLVED OR EXPECTS TO BE INVOLVED IN THE ARRANGEMENT SHALL BE NOTIFIED THAT THE ARRANGEMENT IS NOT AUTHORIZED OR APPROVED AND, IF ALREADY IN EXISTENCE, SHOULD BE TERMINATED. THE PRESIDENT SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY AFTER CONSULTING WITH THE CHAIR OF THE BOARD. THE CHAIR OF THE BOARD SHALL AUTHORIZE OR APPROVE AN ARRANGEMENT ONLY UPON A VOTE OF A MAJORITY OF UNINVOLVED DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15: MERIT RAISES AND BONUSES ARE DETERMINED IN ACCORDANCE WITH PHRMA POLICY BASED ON STAFF EVALUATIONS, AND RECOMMENDATIONS ARE FORWARDED TO THE PRESIDENT FOR REVIEW. OVERALL PERFORMANCE OF THE PRESIDENT OF THE FOUNDATION, INCLUDING MERIT RAISES AND BONUSES, IS ALSO DETERMINED IN ACCORDANCE WITH PHRMA POLICY BASED ON STAFF EVALUATIONS BY THE EX-OFFICIO MEMBER OF THE FOUNDATION BOARD. THIS EVALUATION IS FORWARDED AS ARE RECOMMENDATION TO THE CHAIRMAN AND VICE CHAIR OF THE FOUNDATION BOARD FOR FINAL APPROVAL OF THE PRESIDENT'S PERFORMANCE, INCLUDING COMPENSATION/BONUS. FORM 990, PART VI, SECTION C, LINE 19: THE FOUNDATION DOES NOT MAKE ITS GOVERNING DOCUMENTS OR FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. FORM 990, PART XI, LINE 9: GRANT REFUNDS $37,734 FORM 990, PART XII, LINE 2C: THE AUDIT OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.